Edwards Lifesciences (EW) Long-Term Deferred Tax (2009 - 2026)

Edwards Lifesciences' Long-Term Deferred Tax history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 6.84% year-over-year to $1.1 billion in Q1 2026; TTM through Mar 2026 was $1.1 billion, a 6.84% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 14.72% from the prior year.
• Long-Term Deferred Tax retreated to $1.1 billion in Q1 2026 per EW's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $1.1 billion in Q4 2025 and bottomed at $294.9 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $776.7 million (2024), against an average of $760.3 million.
• Across the five-year window, Long-Term Deferred Tax jumped 98.54% in 2023 and climbed 6.84% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $484.0 million in 2022, then jumped by 54.83% to $749.4 million in 2023, then soared by 32.39% to $992.1 million in 2024, then climbed by 14.72% to $1.1 billion in 2025, then decreased by 3.51% to $1.1 billion in 2026.
• Per Business Quant, the three latest EW Long-Term Deferred Tax figures stand at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025).